NightstaRx and The University of Alberta announce the start of the first Canadian gene therapy study to treat Choroideremia: vision-research.eu

NightstaRx Ltd ("Nightstar"), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies to patients, announces that the University of Alberta, has begun enrolling and dosing subjects in a Phase II clinical trial of the Company's gene therapy for the treatment of choroideremia (CHM).

This gene therapy approach uses a viral vector known as adeno-associated virus (AAV) to deliver a wild-type copy of the Rab-escort protein 1 (REP-1) gene (AAV2-REP1) into cells of the eye.

vision-research.eu - The Gateway to European Vision Research

NightstaRx and The University of Alberta announce the start of the first Canadian gene therapy study to treat Choroideremia

Related Links